These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Metabolic engineering of Escherichia coli for production of (2S,3S)-butane-2,3-diol from glucose.
    Author: Chu H, Xin B, Liu P, Wang Y, Li L, Liu X, Zhang X, Ma C, Xu P, Gao C.
    Journal: Biotechnol Biofuels; 2015; 8():143. PubMed ID: 26379775.
    Abstract:
    BACKGROUND: Butane-2,3-diol (2,3-BD) is a fuel and platform biochemical with various industrial applications. 2,3-BD exists in three stereoisomeric forms: (2R,3R)-2,3-BD, meso-2,3-BD and (2S,3S)-2,3-BD. Microbial fermentative processes have been reported for (2R,3R)-2,3-BD and meso-2,3-BD production. RESULTS: The production of (2S,3S)-2,3-BD from glucose was acquired by whole cells of recombinant Escherichia coli coexpressing the α-acetolactate synthase and meso-butane-2,3-diol dehydrogenase of Enterobacter cloacae subsp. dissolvens strain SDM. An optimal biocatalyst for (2S,3S)-2,3-BD production, E. coli BL21 (pETDuet-PT7-budB-PT7-budC), was constructed and the bioconversion conditions were optimized. With the addition of 10 mM FeCl3 in the bioconversion system, (2S,3S)-2,3-BD at a concentration of 2.2 g/L was obtained with a stereoisomeric purity of 95.0 % using the metabolically engineered strain from glucose. CONCLUSIONS: The engineered E. coli strain is the first one that can be used in the direct production of (2S,3S)-2,3-BD from glucose. The results demonstrated that the method developed here would be a promising process for efficient (2S,3S)-2,3-BD production.
    [Abstract] [Full Text] [Related] [New Search]